N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335, compound 27) showed a specific anti-leukemic activity against FLT3-ITD AML models (MOLM-13, MOLM-14, MV4-11 AML cell lines) when compared with other AML subtypes [68]. Here, FLT3 is linked to acute myeloid leukemia.